Sabinsa’s Curcumin C3 Reduct approved for ANVISA’s IN28 list in Brazil
Curcumin C3 Reduct has earned approval by the National Health Surveillance Agency in Brazil for inclusion on ANVISA’s IN28 list, which allows the product to be introduced and commercialized in food and supplements in Brazil.
Photo © Shutterstock.com/AlexLMX
Sabinsa (East Windsor, NJ) has announced that its Curcumin C3 Reduct has earned approval by the National Health Surveillance Agency in Brazil for inclusion on ANVISA’s IN28 list, which allows the product to be introduced and commercialized in food and supplements in Brazil. Sabinsa’s patented Curcumin C3 Reduct is standardized to 95% tetrahydrocurcuminoids, which are the most active metabolites of curcumin. Sabinsa describes C3 Reduct as a cascading antioxidant, meaning that it can act as an antioxidant for longer and have cumulatively stronger activity.
“Many congratulations to our Sabinsa Brazil team for their first approval. This approval of C3 Reduct marks a significant milestone in the supplement market in Brazil, ushering in the era of Next-Generation of Curcuminoids,” said Sabinsa’s vice president of scientific affairs, Anurag Pande, PhD, in a press release. Pande spearheaded the team for submission to ANVISA.
“Approval of C3 Reduct by ANVISA on the IN28 list is a testament to the science that Sabinsa has created on Curcumin metabolites,” remarked Dr. Majeed. “This is our first approval in the Brazilian market, with more to follow.”
